
    
      This is a single arm, open-label, multi-center, phase I study to determine the efficacy of
      CTL019 in patients with r/r B-cell ALL. The study will have the following sequential phases:
      Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment
      and Primary Follow-up, Secondary Follow-up (if applicable) and Survival Follow-up.
    
  